KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biocryst Pharmaceuticals (BCRX) Shares Outstanding (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Shares Outstanding readings, the most recent being $213.1 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 2.17% to $213.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $213.1 million, a 2.17% increase, with the full-year FY2025 number at $213.1 million, up 2.17% from a year prior.
  • Shares Outstanding hit $213.1 million in Q4 2025 for Biocryst Pharmaceuticals, up from $210.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $213.1 million in Q4 2025 to a low of $177.7 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $189.6 million (2023), compared with a mean of $195.6 million.
  • Biggest five-year swings in Shares Outstanding: rose 15.23% in 2021 and later rose 1.35% in 2024.
  • Biocryst Pharmaceuticals' Shares Outstanding stood at $184.4 million in 2021, then grew by 1.93% to $187.9 million in 2022, then increased by 9.51% to $205.8 million in 2023, then rose by 1.35% to $208.5 million in 2024, then increased by 2.17% to $213.1 million in 2025.
  • The last three reported values for Shares Outstanding were $213.1 million (Q4 2025), $210.5 million (Q3 2025), and $209.9 million (Q2 2025) per Business Quant data.